Meibomian gland dysfunction (MGD) is a common eye condition where the meibomian glands, located in the upper and lower eyelids, may become blocked and do not function properly. These glands secrete an oily substance that forms an essential part of the tear film. When secretion of this oil is obstructed or reduced, moisture evaporates too quickly from the tear film, resulting in dry eye symptoms, eyelid inflammation (blepharitis), and potential damage to the ocular surface. If left untreated, MGD can lead to chronic discomfort and increased risk of permanent damage, highlighting the importance of timely diagnosis and appropriate management.

Forma-I is a non-invasive biopolar radiofrequency treatment to address dry eye symptoms caused by Meibomian Gland Dysfunction (MGD). A small and precise applicator delivers gentle heat to the delicate eye area, thereby targeting the underlying causes of meibomian gland dysfunction, such as gland blockages, and promoting improved blood circulation and gland function.

Bipolar radiofrequency thermal energy also promotes a process called neocollagensis, or the growth and repair of collagen. This helps rebuild and repair the meibomian glands, and results in smoother, tighter, and more youthful-looking skin. By stimulating gland activity and secretion, Forma-I bipolar radiofrequency treatment can help alleviate dry eye symptoms, including discomfort, blurred vision, and irritation, and improve the appearance of fine lines, wrinkles, and bags.

Lumecca Intense Pulsed Light (IPL) treatment delivers targeted light energy to areas of the face, body, and delicate eye area, offering benefits for dry eye, inflammation, and pigmentation concerns. Light energy targets tiny inflammatory blood vessels just below the skin, reducing eyelid inflammation, rosacea, eyelash mites (demodex), and improving collagen synthesis, indirectly helping dry eye symptoms and associated discomfort. Additionally, Lumecca IPL's ability to target pigmented areas can be utilized to address issues like hyperpigmentation, improving the aesthetic appearance around the eyes, areas of the face, and body.

Most patients will start to feel and see improvement after the first treatment, however a series of 4 treatments is typically recommended for optimal results.

Patients over 18 with symptomatic or asymptomatic meibomian gland dysfunction can safely undergo this treatment. There are a few exceptions, such as patients who are pregnant or breastfeeding, or who have existing other existing eye conditions.

These treatments are not recognized by insurance companies as coverable services and are therefore cash pay. These treatments are intended to improve and treat the root cause of dry eye disease, thereby saving money on the lifelong need for expensive prescription eye drops.

Most patients will need 1-2 treatments annually to maintain the results of the initial treatment package.